NCT03830827 is a Phase 4 clinical trial of Vortioxetine in Relapse, sponsored by Sir Run Run Shaw Hospital.

Who is sponsoring NCT03830827?

NCT03830827 is sponsored by Sir Run Run Shaw Hospital.

What drugs are being tested in NCT03830827?

Interventions in NCT03830827: Vortioxetine.

What condition does NCT03830827 study?

NCT03830827 studies Relapse, Cognitive Impairment, Depression.

Is NCT03830827 still recruiting?

NCT03830827 is currently status unknown. Last updated 29 November 2019.

Last reviewed 2019-11-29 · How we verify

NCT03830827

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users

Status unknown Phase 4 Last updated 29 November 2019

What this trial tests

Phase 4 trial testing Vortioxetine in Relapse in 220 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
30 April 2021

30 April 2021

Quick facts

Lead sponsor	Sir Run Run Shaw Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	220
Start date	1 September 2020
Primary completion	30 April 2021
Estimated completion	30 April 2021

Drugs / interventions tested

Vortioxetine (vortioxetine) — full drug profile →

Conditions studied

Relapse — all drugs for Relapse →
Cognitive Impairment — all drugs for Cognitive Impairment →
Depression — all drugs for Depression →

Sponsor

Sir Run Run Shaw Hospital

Who can join

Adults 18 to 65, any sex, with Relapse or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter, double-blind, Randomized, parallel-group study in subjects with methamphetamine dependence was to assess the efficacy of MBRP combined with vortioxetine and MBRP alone on 24-week abstinence rates, improvement of cognition and depressive symptoms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Therapeutic targeting of neuroinflammation in methamphetamine use disorder.
Jeffery N, Mock PY, Yang K, Tham CL, et al · · 2025 · cited 3× · PMID 39727147 · DOI 10.1080/17568919.2024.2447226

Verify or expand the search:

Other trials of Vortioxetine

Trials testing the same drug.

NCT07266545 — RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) · Phase 4 · recruiting
NCT06604520 — Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia · Phase 2 · recruiting
NCT05814640 — Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) · Phase 1, PHASE2 · recruiting
NCT04446039 — Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea · completed
NCT05481957 — Vortioxetine Adjunctive Treatment in Bipolar Depression · Phase 4 · completed

Other recruiting trials for Relapse

Currently open trials in the same condition.

NCT06919939 — Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · Phase 2 · recruiting
NCT06622694 — CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia · Phase 1 · recruiting
NCT06737523 — Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML · Phase 1 · recruiting
NCT06618755 — Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool · NA · recruiting
NCT06686108 — Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relap · Phase 2 · recruiting

Other Sir Run Run Shaw Hospital trials

Trials by the same sponsor.

NCT07453940 — Left Atrial Appendage Closure With Versus Without Pulsed Field Ablation in Atrial Fibrillation Patients With Mild Sympto · NA · recruiting
NCT07508943 — Decision-making and Optimization of Ventilatory Support for AECOPD Patients · not yet recruiting
NCT07514533 — The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma · Phase 2 · not yet recruiting
NCT07350590 — Comparison Between Robotic and Laparoscopic Right Hemicolectomy · terminated
NCT07457073 — AI-Powered Sound Analysis for COPD Screening · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03830827 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sir Run Run Shaw Hospital
Last refreshed: 29 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03830827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing